However, the Average Number of Days of Inpatient Therapy per Patient Treated with an Antibiotic for MRSA Decreased by 10 Percent, According to
New Data Released by Arlington Medical Resources
MALVERN, Penn., June 25 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the number of patients treated with an antibiotic associated with a positive culture for MRSA within U.S. acute care hospitals has increased from 2006 to 2007 by 8 percent. However, the average number of days of inpatient therapy per patient treated with an antibiotic associated with a positive culture for MRSA decreased by 10 percent.
The newly released edition of The U.S. Hospital Antibiotic Market Guide
finds that the most common infections among these patients with a positive
culture for MRSA are:
-- Skin/skin structure infections (46 percent of patients)
-- Systemic infections (19 percent of patients)
-- Lower respiratory infections (19 percent of patients)
Why Pharmaceutical Companies Need this Information
The U.S. Hospital Antibiotic Market Guide allows pharmaceutical companies to quantify the clinical utilization of hospital antibiotics at a highly granular level in the United States. It is the most comprehensive data available to gain insights into clinical usage and prescriber dynamics of hospital antibiotics, including gram positive and gram negative agents.
"With a large pipeline of late-stage anti-MRSA products,
biopharmaceutical companies are demanding accurate information on MRSA
usage patterns and trends so they can understand the current market and how
treatments will evolve with the launch of new anti-MRSA drugs," said Joyce
Wedemeyer, product director at AMR. "The U.S. Hospital Antibiotic Market
Guide allows marketing, new product planning, market research and marketing
teams to understand how
|SOURCE Decision Resources, Inc.|
Copyright©2008 PR Newswire.
All rights reserved